Arca
Skip to content
Tools
Tools

Chronic migraine

Drug research and approvals for chronic migraine: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 59 studies of chronic migraine are recruiting on ClinicalTrials.gov, and Health Canada has authorized 15 drug trials for it since 2013.

  • Recruiting worldwide: 59
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 59 recruiting on ClinicalTrials.gov ↗

How its trials ended

1,356 ClinicalTrials.gov studies of migraine in general, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 388 whose ending is known, 60% met their primary endpoint, 7% missed it and 32% stopped early.

  • Completed, result not reported55741%
  • Ongoing26520%
  • Met its primary endpoint23417%
  • Status unknown14611%
  • Stopped: other or unclear725%
  • Stopped: enrollment or feasibility302%
  • Missed its primary endpoint282%
  • Stopped: lack of efficacy111%
  • Stopped: sponsor or business decision91%
  • Stopped: funding3<1%
  • Stopped: safety1<1%

Trials authorized in Canada

The 10 newest of 15; search them all in Canada trials
Sep 10, 2025A multicentre, randomised, double-blind, placebo-controlled, dose escalation and dose finding phase II study to evaluate the safety and efficacy of IPN10200 in…IPN10200IpsenOngoing
Jul 16, 2025A phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial with extension period to evaluate the efficacy and safety of xeomin®…XeominMerz Therapeutics GmbHOngoing
Mar 6, 2025A phase 3, multicenter, 12-week, double blind, placebo-controlled study to evaluate the safety and efficacy of atogepant for the preventive treatment of…AtogepantAbbVieOngoing
Aug 30, 2023A phase III, randomised, double-blind, placebo-controlled, multicentre, parallel-group study with extension phase to evaluate the efficacy and safety of…Dysport (IPN52120)IpsenOngoing
Mar 4, 2022Long term, open label (dose blinded), extension study of eptinezumab in children and adolescents with chronic or episodic migraineEptinezumabH. Lundbeck A/SOngoing
Mar 4, 2022Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of iv eptinezumab in adolescents (12-17…EptinezumabH. Lundbeck A/SOngoing
Jan 22, 2021A phase 3, multicenter, open-label 156-week extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine…AtogepantAbbVieClosed
Nov 10, 2020A multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety, and tolerability of subcutaneous…AjovyTeva Pharmaceutical IndustriesOngoing
Nov 9, 2020A multicenter, open-label study evaluating long-term safety, tolerability, and efficacy of monthly subcutaneous administration of fremanezumab for the…Ajovy (fremanezumab)Teva Pharmaceutical IndustriesOngoing
Apr 12, 2019"a phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of erenumab in children (6 to < 12 years)…AimovigAmgenOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.